Prognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan-Kettering Cancer Center experience

Clinical Cancer Research

Volumn 10, Issue 18 II, 2004, Pages

  Motzer, Robert J ^a   Bacik, Jennifer ^b   Mazumdar, Madhu ^b   Atkins, Michael ^b   Linehan, W Marston ^b   Gordon, Michael ^b  

^a Memorial Hospital   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CYTOKINE; GEMCITABINE;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; EVALUATION; HISTOLOGY; HUMAN; KIDNEY CARCINOMA; METASTASIS; PATIENT CODING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; UNITED STATES;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 4644354183     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-040031     Document Type: Conference Paper

References (5)

1. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17:2530-40.
2. Motzer RJ, Mazumdar M, Bacik J, Russo P, Berg WJ, Metz E. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 2000;18:1928-35.
3. Motzer RJ, Bacik J, Murphy B, A, Russo P, Mazumdar M. Interferon alfa as a comparative treatment for clinical trials of new therapies against renal cell carcinoma. J Clin Oncol 2002;20:289-96.
4. Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002;20:2376-81.
5. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004:22:454-63.